Lidocaine
Chemotherapy-Induced Neuropathy
Hospital Ambroise Paré ParisSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
27 Active assets in the Chemotherapy-Induced Neuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin University of Rochester | Phase 4 | BB |
Omeprazole Aya Mohamed Sadek Elsaid | Phase 3 | BB |
Pyridoxol Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2/3 | B |
Mecobalamin Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2/3 | B |
Sodium Selenite Pentahydrate Seoul National University Hospital | Phase 3 | B |
View all 44 →
Same molecule, other indications
Lidocaine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →